Big Breakthrough On Coronavirus Vaccine: Nanoparticle Vaccine Candidate Produces COVID-19 Antibodies

David Wessler, a lead author of this paper, said that even a small quantity of this trial vaccine produces a high amount of antibodies in the body.

Tavishi Dogra
Written by: Tavishi DograPublished at: Nov 04, 2020Updated at: Nov 04, 2020
Big Breakthrough On Coronavirus Vaccine: Nanoparticle Vaccine Candidate Produces COVID-19 Antibodies

An experimental vaccine of covid-19 has been developed to give ten times more protection from antibodies of an infected corona patient. Professors at the University of Washington School of Medicine have had this success. It is a nanoparticle vaccine, whose initial testing was successful on mice. Now, this experimental vaccine will be human tested. This investigation is published in the journal Cell. After the corona virus-infected patients recover, antibodies are produced in their body, which helps the person to fight the virus attack again. In this research, the number of antibodies developed in the body by the nanoparticle vaccine (that scientists have prepared) is ten times more than the antibodies of the infected person. That is, antibodies produced on the dose of this experimental vaccine can fight against the virus with ten times more potency. 

How is this more potent than other potential vaccines?

potential vaccines

Researchers say the experimental nanoparticle vaccine they designed is ten times more potent than other potential vaccines for Corona. The microscopic particles formed in it can attack the spike proteins of the coronavirus in large numbers and different ways. On the other hand, most of the potential vaccines for COVID-19 are based on the spike protein present in the pointed outer part of the SARS-Cove-2 virus. Antibodies that develop in the body will not be as potent against that virus. 

Also Read: Cases are rising and the condition is deteriorating as the festive season approaches

Nanoparticle Coronavirus Vaccine

Citing the data of a study on mice of the trial vaccine, which affects the mutation of the virus, the researchers said that it would also be effective on the strain produced after mutation of the virus. Research has shown that after vaccination with this vaccine, the body produces a strong B-cell response. These B-cells are the memory cells of the body's immune system, which retain the experience of fighting the virus for a long time in the body. This keeps the body ready for a long time to fight the coronavirus or its other forms.

Also Read: Patients Recovered From COVID-19 May Still Carry This Virus


Nanoparticle Coronavirus Vaccine

Many COVID-19 vaccines are being developed worldwide due to easy maintenance, but their manufacturing, storage and transport from one place to another is a big challenge. According to the researchers, only a low dose of this vaccine will give protection, which can also be kept outside the freezer, so its worldwide distribution will be easy and economical. Indeed, it is a structure-based vaccine, in which protein nanoparticles bind themselves. Thereby 60 receptors are released at a time, which attaches themselves to the virus that enters the body. While such a large number of proteins are not released in the molecule-based structure, its low dose will also be useful. 

Read More in Latest Health News